HER-2/neu expression in archival non small cell lung carcinomas using FDA-approved Hercep test

Daniela Scheurle, Mohammad Jahanzeb, Richard S. Aronsohn, Laura Watzek, Ramaswamy Narayanan

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

HER-2/neu is a 185 kDa glycoprotein related to the epidermal growth factor receptor. Overexpressed in 25-30% of primary breast carcinomas, HER-2/neu is associated with a poor clinical outcome. Recently the FDA approved an antibody to HER-2/neu, trastuzumab (Herceptin), for the treatment of HER-2/neu overexpressing metastatic breast cancers. Relatively little is known about HER-2/neu status and lung cancers. We reasoned that if HER-2/neu status could be ascertained in non-small cell lung carcinomas (NSCLCs), and a clinical correlation can be established, a rationale for the use of Herceptin in this tumor type could be established. Using a FDA-approved standardized diagnostic kit, HercepTest, for detection of HER-2/neu in clinical specimens, we examined the expression of HER-2/neu in NSCLCs in archival paraffin-embedded specimens (N = 81). In normal epithelium, HER-2/neu expression was not detected in a majority of samples (74/81). HER-2/neu overexpression was detected in 27% of the tumors of different histological types including adenocarcinomas, large cell carcinomas, and squamous cell carcinomas. Poor to moderately differentiated but not well differentiated tumors showed overexpression of HER-2/neu. The specificity of HercepTest was further increased (from 27% to 21%) when the expression in the few normal tissues was subtracted from the tumor score. HER-2/neu may offer an attractive predictive and prognostic factor for NSCLC.

Original languageEnglish
Pages (from-to)2091-2096
Number of pages6
JournalAnticancer Research
Volume20
Issue number3 B
StatePublished - Aug 31 2000
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Neoplasms
Breast Neoplasms
Large Cell Carcinoma
Epidermal Growth Factor Receptor
Paraffin
Squamous Cell Carcinoma
Lung Neoplasms
Glycoproteins
Adenocarcinoma
Epithelium
Antibodies
Trastuzumab

Keywords

  • Adenocarcinomas
  • Differentiation
  • Gene amplification
  • Herceptin
  • Immunohistochemistry

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Scheurle, D., Jahanzeb, M., Aronsohn, R. S., Watzek, L., & Narayanan, R. (2000). HER-2/neu expression in archival non small cell lung carcinomas using FDA-approved Hercep test. Anticancer Research, 20(3 B), 2091-2096.

HER-2/neu expression in archival non small cell lung carcinomas using FDA-approved Hercep test. / Scheurle, Daniela; Jahanzeb, Mohammad; Aronsohn, Richard S.; Watzek, Laura; Narayanan, Ramaswamy.

In: Anticancer Research, Vol. 20, No. 3 B, 31.08.2000, p. 2091-2096.

Research output: Contribution to journalArticle

Scheurle, D, Jahanzeb, M, Aronsohn, RS, Watzek, L & Narayanan, R 2000, 'HER-2/neu expression in archival non small cell lung carcinomas using FDA-approved Hercep test', Anticancer Research, vol. 20, no. 3 B, pp. 2091-2096.
Scheurle, Daniela ; Jahanzeb, Mohammad ; Aronsohn, Richard S. ; Watzek, Laura ; Narayanan, Ramaswamy. / HER-2/neu expression in archival non small cell lung carcinomas using FDA-approved Hercep test. In: Anticancer Research. 2000 ; Vol. 20, No. 3 B. pp. 2091-2096.
@article{cafdf396179b4be9bb60ed34540808d2,
title = "HER-2/neu expression in archival non small cell lung carcinomas using FDA-approved Hercep test",
abstract = "HER-2/neu is a 185 kDa glycoprotein related to the epidermal growth factor receptor. Overexpressed in 25-30{\%} of primary breast carcinomas, HER-2/neu is associated with a poor clinical outcome. Recently the FDA approved an antibody to HER-2/neu, trastuzumab (Herceptin), for the treatment of HER-2/neu overexpressing metastatic breast cancers. Relatively little is known about HER-2/neu status and lung cancers. We reasoned that if HER-2/neu status could be ascertained in non-small cell lung carcinomas (NSCLCs), and a clinical correlation can be established, a rationale for the use of Herceptin in this tumor type could be established. Using a FDA-approved standardized diagnostic kit, HercepTest, for detection of HER-2/neu in clinical specimens, we examined the expression of HER-2/neu in NSCLCs in archival paraffin-embedded specimens (N = 81). In normal epithelium, HER-2/neu expression was not detected in a majority of samples (74/81). HER-2/neu overexpression was detected in 27{\%} of the tumors of different histological types including adenocarcinomas, large cell carcinomas, and squamous cell carcinomas. Poor to moderately differentiated but not well differentiated tumors showed overexpression of HER-2/neu. The specificity of HercepTest was further increased (from 27{\%} to 21{\%}) when the expression in the few normal tissues was subtracted from the tumor score. HER-2/neu may offer an attractive predictive and prognostic factor for NSCLC.",
keywords = "Adenocarcinomas, Differentiation, Gene amplification, Herceptin, Immunohistochemistry",
author = "Daniela Scheurle and Mohammad Jahanzeb and Aronsohn, {Richard S.} and Laura Watzek and Ramaswamy Narayanan",
year = "2000",
month = "8",
day = "31",
language = "English",
volume = "20",
pages = "2091--2096",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "3 B",

}

TY - JOUR

T1 - HER-2/neu expression in archival non small cell lung carcinomas using FDA-approved Hercep test

AU - Scheurle, Daniela

AU - Jahanzeb, Mohammad

AU - Aronsohn, Richard S.

AU - Watzek, Laura

AU - Narayanan, Ramaswamy

PY - 2000/8/31

Y1 - 2000/8/31

N2 - HER-2/neu is a 185 kDa glycoprotein related to the epidermal growth factor receptor. Overexpressed in 25-30% of primary breast carcinomas, HER-2/neu is associated with a poor clinical outcome. Recently the FDA approved an antibody to HER-2/neu, trastuzumab (Herceptin), for the treatment of HER-2/neu overexpressing metastatic breast cancers. Relatively little is known about HER-2/neu status and lung cancers. We reasoned that if HER-2/neu status could be ascertained in non-small cell lung carcinomas (NSCLCs), and a clinical correlation can be established, a rationale for the use of Herceptin in this tumor type could be established. Using a FDA-approved standardized diagnostic kit, HercepTest, for detection of HER-2/neu in clinical specimens, we examined the expression of HER-2/neu in NSCLCs in archival paraffin-embedded specimens (N = 81). In normal epithelium, HER-2/neu expression was not detected in a majority of samples (74/81). HER-2/neu overexpression was detected in 27% of the tumors of different histological types including adenocarcinomas, large cell carcinomas, and squamous cell carcinomas. Poor to moderately differentiated but not well differentiated tumors showed overexpression of HER-2/neu. The specificity of HercepTest was further increased (from 27% to 21%) when the expression in the few normal tissues was subtracted from the tumor score. HER-2/neu may offer an attractive predictive and prognostic factor for NSCLC.

AB - HER-2/neu is a 185 kDa glycoprotein related to the epidermal growth factor receptor. Overexpressed in 25-30% of primary breast carcinomas, HER-2/neu is associated with a poor clinical outcome. Recently the FDA approved an antibody to HER-2/neu, trastuzumab (Herceptin), for the treatment of HER-2/neu overexpressing metastatic breast cancers. Relatively little is known about HER-2/neu status and lung cancers. We reasoned that if HER-2/neu status could be ascertained in non-small cell lung carcinomas (NSCLCs), and a clinical correlation can be established, a rationale for the use of Herceptin in this tumor type could be established. Using a FDA-approved standardized diagnostic kit, HercepTest, for detection of HER-2/neu in clinical specimens, we examined the expression of HER-2/neu in NSCLCs in archival paraffin-embedded specimens (N = 81). In normal epithelium, HER-2/neu expression was not detected in a majority of samples (74/81). HER-2/neu overexpression was detected in 27% of the tumors of different histological types including adenocarcinomas, large cell carcinomas, and squamous cell carcinomas. Poor to moderately differentiated but not well differentiated tumors showed overexpression of HER-2/neu. The specificity of HercepTest was further increased (from 27% to 21%) when the expression in the few normal tissues was subtracted from the tumor score. HER-2/neu may offer an attractive predictive and prognostic factor for NSCLC.

KW - Adenocarcinomas

KW - Differentiation

KW - Gene amplification

KW - Herceptin

KW - Immunohistochemistry

UR - http://www.scopus.com/inward/record.url?scp=0033869769&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033869769&partnerID=8YFLogxK

M3 - Article

C2 - 10928158

AN - SCOPUS:0033869769

VL - 20

SP - 2091

EP - 2096

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 3 B

ER -